Observational studyAsian Pacific journal of cancer prevention : APJCP2025
Characteristics of Successful Third-Line Eradication of Helicobacter pylori based on Antibiotic Susceptibility.
Observational study in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Evolving landscape of potassium-competitive acid blockers: toward disease-specific use beyond acid suppression.Journal of gastroenterology · 2026Review
- Some Newer Antibiotics Active AgainstAntibiotics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRegimens using vonoprazan (VPZ), amoxicillin (AMX), and sitafloxacin (STFX) have been reported to be effective for the third-line eradication of Helicobacter pylori and are widely used in Japan. However, the outcomes of these therapies have only been reported by a limited number of institutions. We aimed to investigate the backgrounds and treatment outcomes of patients who underwent successful third-line eradication of H. pylori.
methodsThis was a single-center, retrospective, observational study included patients who underwent antibiotic susceptibility testing and third-line eradication of H. pylori between 2013 and 2020. We examined the success rates of the third-line regimens and compared the backgrounds and clinical characteristics of patients between the successful and failed eradication groups.
resultsFifty-three patients were enrolled. The overall success rate of third-line eradication was 79.2% (42/53 patients). The most commonly used regimens included proton pump inhibitors (PPI) or VPZ, AMX, and STFX (n=43). The success rate of the VPZ, AMX, and STFX regimens was 89.7% (26/29), whereas that of the PPI, AMX, and STFX regimens was 64.3% (9/14). In the comparison between the success and failure groups, the number of female patients (P=0.001) and AMX sensitivity (P=0.028) were significantly higher in the success group than in the failure group. VPZ use and STFX sensitivity were also more common in the successful group, although the differences were not significant.
conclusionVPZ, AMX, and STFX regimens were the most common and effective regimens, with female and AMX-sensitive patients more likely to have successful third-line eradication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.